🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Adaptive Biotechnologies Corporation ADPT R2KR3KPHARMA

Healthcare · Diagnostics & Research · United States
https://www.adaptivebiotech.com
Company Profile ↓
$24.28
+86.77% 1Y
Mkt Cap$3.86B
P/E-60.70
P/B27.76
52W High$26.44
52W Low$12.30
Book Value$0.90
EPS (TTM)$-0.40

Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 28.0% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $276.98M (+54.8% YoY); net profit $-59.50M.
  • Trailing 12 Months Year-on-year growth — revenue +21.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 28.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:28.00%
1 Year:21.50%

Stock Price Performance

1 Year:+86.77%
6 Months:+63.39%
3 Months:+43.67%
1 Month:+2.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 85% of range
$12.30 $26.44
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)48.44 · Neutral
Price Performance
1M+2.88%
3M+43.67%
6M+63.39%
1Y+86.77%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 28.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-60.70
Industry PE
25.17
Forward P/E
-131.44
PEG Ratio
-
Book Value
$0.90
Price to Book
27.76
P/S
12.87
EV/EBITDA
-180.07
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
28.00%
Profit 5Y
-
Revenue (YoY)
21.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
-13.51%
ROE
-38.76%
ROA
-4.12%
Profit Margin
-20.73%
Op Margin
-22.04%
Gross Margin
46.94%
EPS (Latest Qtr)
$-0.25
EPS (TTM)
$-0.40

Balance Sheet & Liquidity

Debt/Equity
2.72
Quick Ratio
4.51
Current Ratio
4.79
Debt
$410.50M
Total Assets
$640.68M
Current Assets
$291.81M
Working Capital
$210.27M

Ownership

Promoter Holding
1.31%
Chg in Prom Hold
-0.08%
FII / Inst Holding
99.24%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$3.86B
Total Revenue (TTM)
$308.08M
EBITDA
$-21.33M
Free Cash Flow
$18.98M
Operating Cash Flow
$-21.01M
Shares Outstanding
159.06M
Gross Margin
46.94%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ADPT Adaptive Biotechnologies Corporation R2KR3KPHARMA 24.28 -60.70 $3.86B 0.00% -13.51% -38.76% 28.00% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 11.57M17.19M12.67M22.14M26.06M20.91M20.99M26.30M38.44M38.51M39.47M38.62M43.66M47.83M37.65M48.93M37.92M41.87M43.19M--52.44M58.88M93.97M71.68M70.87M-
Cost of Revenue ---------------------16.98M18.00M18.16M18.22M18.71M-
Gross Profit ---------------------35.46M40.88M75.82M53.46M52.17M-
Operating Expenses ---------------------65.07M65.92M65.53M66.23M71.37M-
Operating Income -13.31M-9.16M-20.05M-16.11M-18.05M-34.62M-36.91M-37.05M-41.28M-49.77M-56.33M-63.07M-52.50M-45.43M-57.19M-47.82M-50.96M-48.76M-47.32M---29.60M-25.04M10.29M-12.77M-19.21M-
EBITDA ----------------------22.19M-18.14M16.92M-6.43M-13.29M-
Interest Expense ---------------------2.90M2.95M2.97M2.95M2.89M-
Pretax Income ----------------------29.83M-25.59M9.54M-13.58M-20.02M-
Tax Provision ---------------------------
Net Income -12.49M-8.29M-18.39M-15.66M-13.95M-31.40M-33.53M-36.72M-40.64M-49.30M-55.90M-62.74M-52.05M-45.28M-57.70M-47.81M-50.30M-47.51M-46.22M---29.85M-25.61M9.55M-13.58M-20.03M-
Diluted EPS ----------0.35-0.40-0.44-0.37-0.32-0.40-0.33-0.35-0.33-0.31----0.170.06-0.09-0.13-0.25
R&D Expense 9.45M9.78M12.48M16.53M20.51M23.93M25.99M30.31M33.77M37.80M36.07M37.84M37.04M35.66M32.60M32.24M28.53M30.25M25.35M24.16M-24.20M24.13M23.67M-23.62M-

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 38.45M55.66M85.07M98.38M154.34M185.31M170.28M178.96M276.98M
Cost of Revenue -----57.91M75.55M72.08M71.36M
Gross Profit -----127.40M94.72M106.88M205.62M
Operating Expenses -----327.58M296.33M262.22M262.74M
Operating Income -44.48M-49.76M-78.39M-152.82M-208.97M-200.19M-201.61M-155.34M-57.12M
EBITDA ------175.21M-189.27M-128.76M-29.85M
Interest Expense -----4.24M13.80M11.58M11.78M
Pretax Income ------200.37M-225.30M-159.59M-59.46M
Tax Provision ---------
Net Income -42.83M-46.45M-68.61M-146.23M-207.28M-200.19M-225.25M-159.49M-59.50M
Diluted EPS ----1.11-1.48-1.40-1.56-1.08-0.39
R&D Expense 32.00M39.16M70.70M116.07M142.34M141.76M122.12M102.95M93.77M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --332.69M912.30M1.12B-856.62M661.13M539.38M512.74M
Current Assets ------562.15M410.19M283.75M300.19M
Cash & Equivalents --55.03M96.58M123.44M-90.03M65.06M47.92M70.50M
Inventory ------14.45M14.45M8.44M9.82M
Receivables ------40.06M37.97M41.73M50.37M
Total Liabilities --29.94M341.26M373.15M-392.52M352.86M336.89M287.74M
Current Liabilities --22.80M78.31M105.20M-109.79M88.02M98.05M89.92M
Long Term Debt ----------
Total Debt ------108.00M98.77M89.39M79.15M
Total Equity -189.73M-224.62M-258.11M571.04M743.27M-464.17M308.40M202.71M218.79M
Shares Outstanding ------143.11M145.08M147.77M153.78M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -34.86M-32.26M205.40M-149.68M--183.94M-156.32M-95.21M-45.99M
Investing Cash Flow 36.43M736.00K-481.70M-117.04M-2.90M129.65M77.79M37.95M
Financing Cash Flow 50.03M1.25M319.92M293.59M-132.26M2.25M241.00K30.40M
Capital Expenditure -2.42M-6.30M-11.20M-18.80M--16.35M-10.70M-3.66M-2.96M
Free Cash Flow -37.28M-38.56M194.20M-168.49M--200.29M-167.02M-98.88M-48.95M
Net Change in Cash ------48.77M-24.43M-17.18M22.37M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----68.7%55.6%59.7%74.2%
Operating Margin % -115.7%-89.4%-92.1%-155.3%-135.4%-108.0%-118.4%-86.8%-20.6%
Net Margin % -111.4%-83.4%-80.6%-148.6%-134.3%-108.0%-132.3%-89.1%-21.5%
ROE % 19.1%18.0%-12.0%-19.7%--43.1%-73.0%-78.7%-27.2%
ROCE % --16.1%-9.4%-15.1%--26.8%-35.2%-35.2%-13.5%

Shareholding Pattern

Insiders
1.31%
Institutions
99.24%
Public Float
100.56%

Top Institutional Holders

#Holder% HeldSharesValue
1 Viking Global Investors, L.P. 18.79% 29.99M $755.54M
2 Blackrock Inc. 9.49% 15.14M $381.36M
3 Vanguard Capital Management LLC 4.01% 6.40M $161.31M
4 Wellington Management Group, LLP 3.70% 5.91M $148.91M
5 Vanguard Portfolio Management LLC 3.43% 5.48M $137.95M
6 Shaw D.E. & Co., Inc. 2.90% 4.63M $116.53M
7 Westfield Capital Management Co LP 2.67% 4.27M $107.50M
8 Geode Capital Management, LLC 2.28% 3.64M $91.74M
9 State Street Corporation 2.17% 3.46M $87.12M
10 Invesco Ltd. 1.94% 3.09M $77.94M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADPT

Yahoo Finance Fri, 21 Aug 2026

Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.

Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging from $17 to $30. Investor focus has shifte…

Yahoo Finance hu, 30 Jul 2026

Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

Yahoo Finance Wed, 29 Jul 2026

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates …

Yahoo Finance Wed, 29 Jul 2026

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?…

Yahoo Finance Wed, 29 Jul 2026

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined f…

Yahoo Finance Fri, 24 Jul 2026

Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In

Investors are watching Adaptive Biotechnologies (ADPT) after forecasts pointed to a reduced quarterly loss of $0.13 per share and 12.6% revenue growth for the June 2026 quarter, alongside its track record of beating earnings estimates. See …

ADPT — Frequently Asked Questions

What is the current share price of Adaptive Biotechnologies Corporation (ADPT)?

As of 2026-09-07 16:24 PDT, Adaptive Biotechnologies Corporation (ADPT) trades at $24.28 on NasdaqGS. Its 52-week range is $12.30 to $26.44.

What is the market capitalisation of ADPT?

Adaptive Biotechnologies Corporation (ADPT) has a market capitalisation of $3.86B on NasdaqGS.

What is the P/E ratio of ADPT?

ADPT trades at a trailing price-to-earnings (P/E) ratio of -60.70. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 27.76.

What is the return on equity (ROE) of ADPT?

ADPT has a return on equity (ROE) of -38.76%. Its return on capital employed (ROCE) is -13.51%.

Is ADPT a good stock to buy?

This page provides a data-driven analysis of Adaptive Biotechnologies Corporation (ADPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space